Novo Nordisk (NVO) said Thursday that Executive Vice President of Commercial Strategy and Corporate Affairs Camilla Sylvest has decided to depart.
The company said EVP of Rare Disease Ludovic Helfgott will assume the responsibility for product and portfolio strategy, while Senior Vice President of Product Supply Emerging Technologies Thilde Hummel Bogebjerg was promoted to EVP of quality, IT and environmental affairs.
EVP of People and Organization Tania Sabroe is assuming the additional responsibility for global communication, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。